Article Versions Notes

Athanasiou A, Hansen TF, Madsen JS, Poulsen MH, Mortensen MA, Kissow GE, Øbro LF, Osther PJ, Schiess R, Zedan AH. The Prognostic Value of Proclarix in Prostate Cancer Patients Under Active Surveillance: Predicting Transition to Active Treatment and Disease Progression in a Danish Cohort. Cancers. 2026; 18(9):1348. https://doi.org/10.3390/cancers18091348

Athanasiou, Alcibiade, Torben F. Hansen, Jonna S. Madsen, Mads H. Poulsen, Mike Allan Mortensen, Gitte E. Kissow, Louise F. Øbro, Palle J. Osther, Ralph Schiess, and Ahmed H. Zedan. 2026. "The Prognostic Value of Proclarix in Prostate Cancer Patients Under Active Surveillance: Predicting Transition to Active Treatment and Disease Progression in a Danish Cohort" Cancers 18, no. 9: 1348. https://doi.org/10.3390/cancers18091348

Athanasiou, A., Hansen, T. F., Madsen, J. S., Poulsen, M. H., Mortensen, M. A., Kissow, G. E., Øbro, L. F., Osther, P. J., Schiess, R., & Zedan, A. H. (2026). The Prognostic Value of Proclarix in Prostate Cancer Patients Under Active Surveillance: Predicting Transition to Active Treatment and Disease Progression in a Danish Cohort. Cancers, 18(9), 1348. https://doi.org/10.3390/cancers18091348